Role of Huperzine a in the Treatment of Alzheimer's Disease

Desilets, Alicia R; Gickas, Jennifer J; Dunican, Kaelen C

doi:10.1345/aph.1l402

Cited by 54 publications

(33 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In secondary analyses, huperzine A 400 μg BID showed a 2.27-point improvement in ADAS-Cog at 11 weeks vs 0.29-point decline in the placebo group (p = 0.001), and a 1.92-point improvement vs 0.34-point improvement in the placebo arm (p = 0.07) at week 16 [153]. Therefore, overall Huperzine A is a well-tolerated drug that could significantly improve cognitive performance in patients with AD, and it appears to be more effective than FDA approved acetylcholinesterase inhibitors, AChEIs [150, 154-156]. Considering the study design was not strong, sample sizes were still small, as well as individuals vary for an optimal effective dose, rigorous design, randomized, multi-centre, large-sample trials of Huperzine A and its derivatives for AD are needed to further assess the effects.…”

Section: Dna Damage In Alzheimer's Diseasementioning

confidence: 99%

Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics

Mao

Reddy

2011

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

271

190

View full text Add to dashboard Cite

Alzheimer's disease (AD) is an age-related progressive neurodegenerative disease affecting thousands of people in the world and effective treatment is still not available. Over two decades of intense research using AD postmortem brains, transgenic mouse and cell models of amyloid precursor protein and tau revealed that amyloid beta (Aβ) and hyperphosphorylated tau are synergistically involved in triggering disease progression. Accumulating evidence also revealed that aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction initiates and contributes to the development and progression of the disease. The purpose of this article is to summarize the latest progress in aging and AD, with a special emphasis on the mitochondria, oxidative DNA damage including methods of its measurement. It also discusses the therapeutic potential of oxidative DNA damage and treatment strategies in AD.

show abstract

Section: Dna Damage In Alzheimer's Diseasementioning

confidence: 99%

Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics

Mao

Reddy

2011

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

271

190

View full text Add to dashboard Cite

show abstract

“…The Lycopodium alkaloids, consisting of over 200 isolated members with various architectures, have exhibited impressive biological activities 35,36 . Among these alkaloids, huperzine A, with particularly potent acetylcholinesterase inhibitory activity, has been used for the treatment of neurodegenerative disorders 37 , and Serratezomine A showed cytotoxicity against murine lymphoma L1210 cells (IC 50 ¼ 9.7 mg ml À 1 ) and human epidermoid carcinoma KB cells (IC 50 410 mg ml À 1 ) (ref. 38).…”

Section: Resultsmentioning

confidence: 99%

Diversity-oriented synthesis of Lycopodium alkaloids inspired by the hidden functional group pairing pattern

Zhang

Hong

et al. 2014

Nat Commun

View full text Add to dashboard Cite

“…The molecules with minimum energy and which had shown binding with the active site of Acetylcholinesterase has been selected. They are Huperzine A [14], Galantamine, Tesofensine, …”

Section: Resultsmentioning

confidence: 99%

In-Silico Identification of Potential Inhibitors Against AChE Using Cheminformatics Approach

Gupta¹

2014

MOJPB

View full text Add to dashboard Cite

Acetylcholinesterase (AChE) is highly viable target in Alzheimer's disease (AD) as cholinergic deficit is consistent and early finding in AD. From previous studies, it has been proved that the Cholinesterase inhibitors (ChE-Is) are the only class of drugs approved by the Food and Drug Administration (FDA) for treatment of AD. Comparison of inhibitory activity of 15 different ChE-Is class of drugs was performed using cheminformatics and molecular docking approach against AChE. This approach helps to identify the binding affinity, mode of interaction and to understand the selectivity of drug molecule for the treatment of Alzheimer's disease. This article suggests the best market available ChE-Is for AD.

show abstract

Role of Huperzine a in the Treatment of Alzheimer's Disease

Abstract: Although use of huperzine A has shown promising results in patients with AD, data supporting its use are limited by weak study design. Largescale, randomized, placebo-controlled trials are necessary to establish the role of huperzine A in the treatment of AD.

Cited by 54 publications

References 9 publications

Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics

Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics

Diversity-oriented synthesis of Lycopodium alkaloids inspired by the hidden functional group pairing pattern

In-Silico Identification of Potential Inhibitors Against AChE Using Cheminformatics Approach

Contact Info

Product

Resources

About